1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Research Methodology
2.1. Qualitative Research
2.1.1. Primary & Secondary Research
2.2. Quantitative Research
2.3. Market Breakdown & Data Triangulation
2.3.1. Secondary Research
2.3.2. Primary Research
2.4. Breakdown of Primary Research Respondents
2.5. Assumption & Limitation
3. Executive Summary
4. United States Human Insulin Market Insights
4.1. Industry Value Chain Analysis
4.2. DROC Analysis
4.2.1. Growth Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Technological Advancement/Recent Development
4.4. Regulatory Framework
4.5. Porters Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Intensity of Rivalry
5. United States Human Insulin Market Overview
5.1. Market Size & Forecast by Value, 2018-2028
5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
5.2.1. By Product Type
5.2.1.1. Human Insulin Drugs
5.2.1.2. Human Insulin Delivery Devices
5.2.2. By Type
5.2.2.1. Insulin Analogs and Biosimilars
5.2.2.1.1. Long-Acting Biosimilars
5.2.2.1.2. Rapid-Acting Biosimilars
5.2.2.1.3. Premixed Biosimilars
5.2.2.2. Human Insulin Biologics
5.2.2.2.1. Short-Acting Biologics
5.2.2.2.2. Intermediate-Acting Biologics
5.2.2.2.3. Premixed Biologics
5.2.3. By Delivery Devices
5.2.3.1. Syringes
5.2.3.2. Pens
5.2.3.2.1. Disposable Pens
5.2.3.2.2. Reusable Pens
5.2.3.3. Pen Needles
5.2.3.3.1. Standard Pen Needles
5.2.3.3.2. Safety Pen Needles
5.2.4. By Application
5.2.4.1. Type I Diabetes
5.2.4.2. Type II Diabetes
5.2.5. By Distribution Channel
5.2.5.1. Retail Pharmacies
5.2.5.2. Hospital Pharmacies
5.2.5.3. Online Pharmacies
6. Competitive Landscape
6.1. List of Key Players and Their Offerings
6.2. Market Share Analysis, 2021
6.3. Competitive Benchmarking, By Operating Parameters
6.4. Key Strategic Development (Merger, Acquisition, Partnership.)
7. Impact of Covid-19 on United States Human Insulin Market
8. Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) **
8.1. AstraZeneca PLC
8.2. Biocon Limited
8.3. Dongbao Enterprise Group Co., Ltd.
8.4. Eli Lilly and Company
8.5. GmbH
8.6. Julphar
8.7. Novartis International AG
8.8. Novo Nordisk A/S
8.9. Pfizer Inc.
8.10. Sanofi SA
8.11. Tonghua Dongbao Pharmaceutical Co., Ltd
8.12. Wockhardt Ltd
8.13. Other prominent players
9. Key Strategic Recommendations
*Financial information in case of non-listed companies will be provided as per availability
**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable